# **Product** Data Sheet

## MC-GGFG-Exatecan

 $\begin{array}{lll} \textbf{Cat. No.:} & \textbf{HY-114233} \\ \textbf{CAS No.:} & 1600418-29-8 \\ \textbf{Molecular Formula:} & \textbf{C}_{_{49}}\textbf{H}_{_{51}}\textbf{FN}_{_{8}}\textbf{O}_{_{11}} \\ \end{array}$ 

Molecular Weight: 947


**Target:** Drug-Linker Conjugates for ADC

Pathway: Antibody-drug Conjugate/ADC Related

Storage: Powder -20°C 3 years

In solvent -80°C 6 months

-20°C 1 month



### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (52.80 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.0560 mL	5.2798 mL	10.5597 mL
	5 mM	0.2112 mL	1.0560 mL	2.1119 mL
	10 mM	0.1056 mL	0.5280 mL	1.0560 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description	MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) <sup>[1]</sup> .		
IC <sub>50</sub> & Target	Camptothecins		
In Vitro	In MC-GGFG-Exatecan, GGFG is selectively cleaved by lysosomal enzymes (presumably cathepsins) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	In MC-GGFG-Exatecan, GGFG is known to release drugs into tumor tissue without releasing them into peripheral circulation [1].  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

#### **REFERENCES**

Caution: Product has not been fully validated for medical applications. For research use only.  Tel: 609-226-6898 Fax: 609-228-5009 E-mail: tech@ikedchemExpress.com Address: 1 Deer Park Dr. Suite Q, Monmouth Junction, NJ 08852, USA				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com	1]. Nakada T, et al. Novel antibody	drug conjugates containing exatecan deriv	vative-based cytotoxic payloads. Bioorg Med	Chem Lett. 2016 Mar 15;26(6):1542-1545.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com	C	aution: Product has not been fully vali	dated for medical applications. For res	earch use only.
	Т			

Page 2 of 2 www.MedChemExpress.com